441 related articles for article (PubMed ID: 28717990)
1. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Locatelli F; Del Vecchio L
J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
[TBL] [Abstract][Full Text] [Related]
2. Optimal phosphate control: still an unmet need in chronic kidney disease patients.
Locatelli F; Del Vecchio L
Expert Opin Pharmacother; 2014 Feb; 15(3):307-9. PubMed ID: 24283572
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
4. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
6. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
[TBL] [Abstract][Full Text] [Related]
7. Next-generation phosphate binders: focus on iron-based binders.
Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
[TBL] [Abstract][Full Text] [Related]
8. Current and potential treatment options for hyperphosphatemia.
Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
[TBL] [Abstract][Full Text] [Related]
9. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
10. [Iron-based Phosphate Binders for ESRD Patients].
Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
12. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
14. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
15. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
16. [Current approaches in the treatment of hyperphosphatemia in chronic kidney disease].
Matuszkiewicz-Rowińska J; Kościelska M
Wiad Lek; 2017; 70(6 pt 2):1161-1165. PubMed ID: 29533905
[TBL] [Abstract][Full Text] [Related]
17. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Pai AB; Jang SM; Wegrzyn N
Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous S; Przech S; Martin J; Garg AX; Sarma S
Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
20. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Schmid H; Lederer SR
Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]